Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Recruiting · NCT05965024 · Observational (researchers observe without assigning treatment) · Lead sponsor: Shanghai Pulmonary Hospital, Shanghai, China
View the official record on ClinicalTrials.gov →What this trial is about
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 18 years old, regardless of gender;
- Patients with pathological diagnosis of non-small cell lung cancer and clinical staging of stage IB-IIIB;
- Able to undergo radical surgical treatment;
- Physical condition score (ECOG) ≤1;
- The expected survival time exceeds 24 months;
- Volunteer to participate in this study and sign an informed consent form.
Exclusion criteria
- Individuals with a history of other malignant tumors within 5 years;
- Those who have undergone neoadjuvant therapy before surgery;
- Postoperative incision margin R1 or incision margin R2;
- Those who have undergone a blood transfusion within 2 weeks before the surgery;
- Individuals with systemic inflammatory response syndrome;
- Those with serious diseases of important organs such as the heart, lungs, kidneys, and brain;
- Participants in other clinical trials within the past 30 days and have taken investigational drugs;
- Due to various reasons, sampling cannot be completed, samples do not meet the requirements, or baseline samples (preoperative and postoperative plasma samples, tumor tissue samples) are incomplete;
- Researchers believe that it is not appropriate to participate in this experiment.
Where it is running
1 location listed.
- Shanghai Pulmonary Hospital - Shanghai, Shanghai Municipality, China